Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Akorn, Inc.
Akorn Enters into a Manufacturing and Supply Agreement for the Contract Manufacture of an Ophthalmic Solution
March 2nd, 2008
Akorn, Inc. (NASDAQ:AKRX) announced the signing of a five-year contract manufacturing and supply agreement with a major U.S. pharmaceutical company. Under the terms of the five-year agreement, Akorn will be responsible for the manufacturing and supply of the ophthalmic drug product. This ophthalmic drug product will be manufactured at the Company's Somerset, NJ facility. Akorn is the ANDA holder and also expects to launch this drug product under the Akorn label in mid-2008. The current market size is approximately $25 million, according to recent IMS sales data. Arthur S. Przybyl, Akorn's President and Chief Executive Officer stated, "We are very pleased to have been...
Source: Pharma Investments, Ventures & Law Weekly (2008-03-02)
|
